Share Share on Facebook Share on Twitter Pinterest Email Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial Download the PDF here. This post appeared first on investingnews.com 0 Related Posts Nebius Shares Soar on US$17.4 Billion Microsoft AI Deal September 10, 2025 From Cartier to Cardboard Boxes: Pop Culture’s Most Iconic Rocks September 10, 2025 Locksley Resources LimitedAdvances Antimony Supply Strategy September 10, 2025